Lactulose Market To Reach $732.0 Million By 2030 | CAGR: 6.4%

May 2025 | Report Format: Electronic (PDF)

Lactulose Market Growth & Trends

The global lactulose market size is anticipated to reach USD 732.0 million by 2030 and is anticipated to grow at a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for lactulose is rising prevalence of chronic constipation and liver-related disorders, particularly among the aging population. As a non-invasive and effective treatment, lactulose is widely prescribed for conditions like hepatic encephalopathy and irritable bowel syndrome.

The syrup/liquid segment dominated the market with a revenue share of 57.6% in 2024, during the forecast period. lactulose syrup plays a key role in managing hepatic encephalopathy, a serious complication of liver disease where patients experience high levels of ammonia in the blood. In such cases, lactulose is used to reduce ammonia absorption and improve mental status. Since these conditions require ongoing treatment, the syrup form is often used in long-term care and hospital protocols. The convenience of ready-to-use liquid packaging, availability across pharmacies, and frequent use in clinical prescriptions further contribute to its high volume consumption and market value.

The laxative segment dominated the market with a revenue share of 69.8% in 2024, during the forecast period. The segment in the lactulose market is essential as populations age particularly in countries like Japan, Germany, and the U.S.-the need for safe, effective laxatives has grown. Lactulose is also frequently recommended by physicians due to its dual benefit: not only does it relieve constipation, but it also improves gut flora, promoting overall digestive health. Available in various forms, including syrup, powder, and tablets, lactulose’s flexibility in administration enhances its appeal

Asia Pacific dominated the market with a market share of 37.3% in 2024, during the forecast period. The Asia-Pacific region leads the lactulose market, driven by the rise in infant formula and functional drink markets, especially in China and South Korea, is boosting demand in the food & beverage segment. Moreover, local pharmaceutical manufacturing and a push for prebiotics in wellness trends are accelerating demand across Asia Pacific.

Some prominent players in the lactulose market include Fresenius Kabi, Orion Lifescience, Morinaga Milk Industry Co., Ltd., Abbott, Illovo, Biofac, Daiichi Sankyo, Inalco SpA, Casca Remedies, and Enrich Pharma.

key Request a free sample copy or view report summary: Lactulose Market Report

Lactulose Market Report Highlights

Based on form, the powder segment is expected to grow the fastest with a CAGR of 6.9% during the forecast period. Powdered forms are more suitable for export and global distribution, particularly to regions with limited cold-chain infrastructure. Its ability to be reconstituted into solutions as needed also makes it versatile for both commercial and clinical applications, fueling its steady demand across various segments.
Based on function, the laxative segment dominated the market and accounted for the largest revenue share of 69.8% in 2024. This is due to its long-standing and widespread use in treating constipation, especially in chronic and age-related cases
Based on application, the pharmaceuticals segment dominated the market and accounted for the largest revenue share of 77.6% in 2024. This is driven by the therapeutic uses of lactulose, particularly as a laxative and for managing hepatic encephalopathy (HE).
Based on region, Asia Pacific is the dominant region for the lactulose market with a revenue share of 37.3% in 2024. This growth is attributed to increasing population and increasing demand for lactulose. Countries like China, India, and Japan are driving demand through infrastructure development and an increasing geriatric population in the region.
In February 2024, Windzor Pharma Ltd launched Brillphalac (Lactulose) oral solution in Ireland on January 10, 2024. The product is available in 500ml (reimbursed under HSE schemes) and 300ml (OTC in pharmacies) pack sizes, marking a key addition to their gastrointestinal product portfolio.